上海信帆生物科技有限公司 全國咨詢熱線：13814106335
PRODUCT CLASSIFICATION
產品分類
更新時間：2022-04-24 
瀏覽次數：1470熱烈祝賀我司客戶又一篇SCI文章被國際期刊收錄
祝賀我司客戶的優質研究成果被國際期刊《Clinical Rheumatology》收錄
該論文中所使用的以下ELISA試劑盒均購自我司。
Human IL-34 ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)
Human TNF-a ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)
Human IL-6 ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)
Human IL-8 ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)
Human MMP-3 ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)
信帆生物是一家專業的elisa試劑盒供應商,銷售各種進口國產品牌的elisa試劑盒。
對于elisa試劑盒,我們提供完善的質量保證,專業的技術解答,耐心周到的售后服務,成為國內多家科研機構和高校的試劑盒供應商。
信帆生物從創立至今，具有多年試劑領域的研發、生物試劑和銷售經驗，目前已經成長為國內規模較大的試劑研發、生物試劑和銷售的綜合性企業，一直為科研工作者助力。我們期待您的光臨！
該論文標題： Predictors of response to TNFα antagonist therapy in Chinese rheumatoid arthritis
Clinical Rheumatology
期刊號：Issue 7, pp 1203–1210
老師在論文后期編輯過程中與我們積極互動，信帆生物給予了支持，最終順利被《Clinical Rheumatology》錄用。
以下是老師論文中使用我司產品的截圖
熱烈祝賀上海信帆客戶又一篇SCI文章被國際期刊收錄
《Clinical Rheumatology》期刊介紹：
Clinical Rheumatology is an international journal devoted to publishing in the English language original clinical investigation and research in the general field of rheumatology with accent on clinical aspects at postgraduate level. Studies carried out anywhere in the world will be considered the basic criterion for acceptance being the medical and scientific standard of the work described.
文章介紹
This study aimed to investigate the clinical, immunological, and radiologic predictors of response to tumor necrosis factor (TNF)-α antagonist therapy in Chinese rheumatoid arthritis (RA). Ninety RA patients were divided into two groups according to their responsiveness to TNF-α antagonist therapy at 1 month: group A (responders) and group B (non-responders). After 3 months of therapy, all the 90 patients were re-assessed and re-divided into another two groups: group C (responders) and group D (non-responders). Serum samples and clinical characteristics as well as radiographic features were collected at baseline, first month, and third month post-initial administration of TNF-α antagonist. Serum TNF-α, interleukin (IL)-6, IL-8, IL-34, and matrix metalloproteinase (MMP)-3 were measured by enzyme-linked immunosorbent assay (ELISA). Disease activity and Sharp score were evaluated. (1) Comparisons between groups A and B: subjects in group A showed a lower level of erythrocyte sedimentation rate (ESR) and a higher level of albumin (ALB) at baseline than that of group B (p?<?0.05). The cutoff value of ALB for prediction was ≥34.9 g/l and that of ESR was ≤55.5 mm/h. (2) Comparisons between groups C and D: group C showed lower levels of ESR, health assessment questionnaire (HAQ), and IL-34 at baseline (p?<?0.05). The threshold for prediction were as follows: ESR ≤60 mm/h, HAQ ≤1.3125, and IL-34 ≤194.12 pg/ml. (3) The serum cytokines were positively correlated with C-reactive protein (CRP) and disease activity index, while ALB was negatively correlated with CRP and disease activity. Baseline ALB ≥34.9 g/l or ESR ≤55.5 mm/h might predict a good response at 1-month treatment of TNF-α antagonist, while baseline ESR ≤60 mm/h, HAQ ≤1.3125, and IL-34 ≤194.12 pg/ml might predict a good response at 3-month treatment.
您的位置：
